- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation
- Interventions
- CID-078 Monotherapy
- Drug
- Lead sponsor
- Circle Pharma
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 10
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 523
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Submental Fat (SMF), Double Chin
- Interventions
- RJV001, Placebo
- Drug
- Lead sponsor
- Rejuven Dermaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Bioavailability of ASP015K, Pharmacokinetics of ASP015K, Healthy Subjects
- Interventions
- ASP015K
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
- Interventions
- HC-7366
- Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
- Conditions
- Healthy
- Interventions
- Decitabine
- Drug
- Lead sponsor
- EpiDestiny, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- efgartigimod PH20 SC in stage B, placebo in stage B
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Vitiligo
- Interventions
- ruxolitinib, Vehicle
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 44
- States / cities
- Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
- Conditions
- Immunization; Infection|Transplantation Infection|Influenza, Influenza
- Interventions
- Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- COVID-19 Pneumonia
- Interventions
- PF-06650833, Matching Placebo
- Drug
- Lead sponsor
- Giovanni Franchin, M.D, Ph.D
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Influenza
- Interventions
- CAIV-T
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000
- U.S. locations
- 1
- States / cities
- Stamford, Connecticut
- Conditions
- Hypoglycemia
- Interventions
- Glucagon for Injection (Fresenius Kabi USA), Glucagon for Injection (Bedford Laboratories)
- Drug
- Lead sponsor
- Fresenius Kabi USA, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
- Interventions
- Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin
- Device · Drug
- Lead sponsor
- AeRang Kim
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Healthy Volunteers
- Interventions
- Enasidenib
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
- Interventions
- Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
- Conditions
- Alopecia, Baldness
- Interventions
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy Participant
- Interventions
- PF-07220060
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Glioblastoma Multiforme
- Interventions
- Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
- Drug · Radiation · Device
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Interventions
- AMA0076, Placebo
- Drug
- Lead sponsor
- Amakem, NV
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Artesia, California • Inglewood, California • Petaluma, California + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Pomalidomide, All-trans retinoic acid, Dexamethasone
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Meningococcal Immunisation, Healthy Volunteers
- Interventions
- Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 1,215 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
- Interventions
- Vigil, Irinotecan, Temozolomide
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
- Conditions
- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
- Interventions
- Administration of AZD6738
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Locally Advanced Unresectable or Metastatic Melanoma
- Interventions
- Selinexor, Pembrolizumab
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more